- Home
- HRMY vs PRCT Comparison
HRMY vs PRCT Comparison
Compare HRMY & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- PRCT
- Stock Information
- Founded
- HRMY 2017
- PRCT 2009
- Country
- HRMY United States
- PRCT United States
- Employees
- HRMY N/A
- PRCT N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- PRCT Medical Specialities
- Sector
- HRMY Health Care
- PRCT Health Care
- Exchange
- HRMY Nasdaq
- PRCT Nasdaq
- Market Cap
- HRMY 1.9B
- PRCT 2.1B
- IPO Year
- HRMY 2020
- PRCT 2021
- Fundamental
- Price
- HRMY $26.87
- PRCT $34.63
- Analyst Decision
- HRMY Strong Buy
- PRCT Buy
- Analyst Count
- HRMY 10
- PRCT 8
- Target Price
- HRMY $51.30
- PRCT $70.00
- AVG Volume (30 Days)
- HRMY 1.0M
- PRCT 1.0M
- Earning Date
- HRMY 10-28-2025
- PRCT 10-27-2025
- Dividend Yield
- HRMY N/A
- PRCT N/A
- EPS Growth
- HRMY 58.41
- PRCT N/A
- EPS
- HRMY 3.10
- PRCT N/A
- Revenue
- HRMY $772,527,000.00
- PRCT $274,950,000.00
- Revenue This Year
- HRMY $19.94
- PRCT $48.38
- Revenue Next Year
- HRMY $16.65
- PRCT $30.87
- P/E Ratio
- HRMY $8.72
- PRCT N/A
- Revenue Growth
- HRMY 17.74
- PRCT 55.71
- 52 Week Low
- HRMY $26.26
- PRCT $34.01
- 52 Week High
- HRMY $41.61
- PRCT $103.81
- Technical
- Relative Strength Index (RSI)
- HRMY 27.45
- PRCT 36.50
- Support Level
- HRMY $26.56
- PRCT $34.01
- Resistance Level
- HRMY $27.48
- PRCT $36.48
- Average True Range (ATR)
- HRMY 1.01
- PRCT 1.58
- MACD
- HRMY -0.25
- PRCT 0.00
- Stochastic Oscillator
- HRMY 8.99
- PRCT 9.20
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.